News

This second MJFF grant will be used to fund the Company’s CTH-105 clinical study. APL-130277 is an easy-to-administer, fast-acting and proprietary reformulation of apomorphine for sublingual delivery. Injectable

Actavis’ ANDA product is a generic version of Acorda Therapeutics’ Ampyra, which is indicated as a treatment to improve walking in patients with multiple sclerosis. Acorda Therapeutics, Inc.

The FDA acceptance follows the acceptance of the marketing authorization dossier for Toujeo by the European Medicines Agency (EMA) for EU countries in May 2014. The new drug

GelStat acquired 100% of the membership equity in Mastix Medica, LLC in exchange for 27,500,000 restricted shares in GelStat’s common stock. In conjunction with the closing of this

The collaboration provides for the development and commercialization of therapeutic antibodies against two checkpoint protein candidates discovered by Compugen. The milestone being announced today relates to the first

The two companies are partnering to develop a population health management platform solution that leverages CliniWorks’ technologies in disparate data aggregation and Natural Language Processing (which interprets free

The approval makes VIMIZIM the first and only pharmaceutical treatment option available in Canada for children and adults living with this severely debilitating, progressive and life-limiting disorder. "Morquio

Under the terms of the agreement, Mariel acquired the rights to over 450 issued and pending patents, Stryker’s BMP-7-related clinical and research data, and the associated biologic materials.

BGB-290 is an investigational, oral, selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP), an enzyme family which is involved in a number of cellular processes, including DNA